PetVivo Reports Fiscal 2025 Results

Core Insights - PetVivo Holdings, Inc. reported a 17% increase in revenues to a record $1.1 million for the fiscal year ending March 31, 2025, driven by expansion into the companion animal market and strong sales of its lead product, Spryng with OsteoCushion Technology [5][7][31] - The company has made significant operational improvements, including a 24% reduction in operating loss to $8.1 million and a 27% decrease in net loss to $8 million [5][12] - PetVivo has entered strategic partnerships and expanded its product offerings, including a licensing agreement for PrecisePRP and a collaboration with Digital Landia for AI solutions in veterinary care [24][27][29] Fiscal 2025 Financial Highlights - Revenues increased by 17% to $1.1 million, with national distributor network sales rising 31% to $958,000, representing 85% of total revenues [5][12] - Gross profit rose 15% to $995,000, with a gross margin of 87.8% [5][12] - Net cash used in operating activities decreased by 40% to $2.9 million compared to fiscal 2024 [5] Fiscal 2025 Operational Highlights - Spryng has been administered by over 1,000 veterinary clinics across all 50 states since its introduction in 2021 [5][9] - The company signed an exclusive licensing agreement with VetStem, Inc. to commercialize PrecisePRP, receiving positive feedback from veterinarians [24][5] - A strategic alliance with Digital Landia focuses on AI technology for animal behavior analysis, currently in beta testing [27][29] Management Commentary - The CEO highlighted the strong performance and productivity of the fiscal year, emphasizing the expansion into the companion animal market and the introduction of innovative products [7][8] - The company anticipates continued growth driven by new partnerships and technologies that enhance its product platform [8][31] Fiscal 2026 Outlook - For the fiscal year ending March 31, 2026, the company expects record growth and improved bottom line as it continues to expand the use of Spryng and other new products [32][31] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [31]